Rheumaderm pp 331-336 | Cite as


An Alternative Drug for Second-Line Treatment of Juvenile Chronic Arthritis
  • Boriana B. Varbanova
  • E. D. Dyankov
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)


Sulphasalazine has been established to be an effective drug for second line treatment of early mild to moderate rheumatoid arthritis. Its application for juvenile chronic arthritis (JCA) is limited so far and controversial results for the efficacy of this therapy have been published. We studied the efficacy and tolerance of the sulphasalazine treatment in 32 patients with JCA (10 with polyarthritis, 21 with pauciarthritis and 1 with systemic form). Our results revealed significant response of the treatment at the end of the 6th month in 24/31 patients (77%). In one patient the treatment was discontinued because of transitory neutropenia at the end of the 1st month. No significant difference was observed between the efficacy of the treatment in the polyarticular and pauciarticular disease, as well as newly-diagnosed cases and those with longstanding disease. From the group of 17 children treated up to the end of the 1st year 88% achieved complete remission. No serious toxic effects were observed, with the exception of two cases with transitory low-grade neutropenia.

According to our results sulphasalazine is an effective and well tolerated drug for second line treatment of JCA-patients.


Rheumatoid Arthritis Complete Remission Juvenile Rheumatoid Arthritis Juvenile Chronic Arthritis Early Rheumatoid Arthritis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wijnands M J H, Van’t Hof M A, L.B.A. van de Putte et al. Rheumatoid arthritis: A risk factor for sulphasalazine toxicity? A meta-analysis. Brit J Rheumatol, 32, 313–318. (1993)CrossRefGoogle Scholar
  2. 2.
    Porter D R, Mclnnes I B, Hunter J et al. Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis, 53, 812–815. (1994)PubMedCrossRefGoogle Scholar
  3. 3.
    Farr L F, Palmer R.G., Bacon P.A.. Sulphasalazine in rheumatoid arthritis; Long term tolerability in 432 patients monitored for 2 to 15 years. Arthritis Rheum, 37, 578 abstr. (1994)CrossRefGoogle Scholar
  4. 4.
    Van Riel P L C M, van Gestel A.M., Prevoo M.L.L. et al. Long term experience with sulphasalazine in a cohort of early rheumatoid arthritis patients. Arthritis Rheum, 37, 579 abstr. (1994)Google Scholar
  5. 5.
    Wijnands M J H, Van’t Hof M.A., van Leeuwen M.A. et al. Long term second-line treatment: A prospective drug “survival” study. EULAR-bulletin, 1993, 1,10–14.Google Scholar
  6. 6.
    Felson D, Anderson J.J., Meenan R. Use of short-term efficacy/ toxicity trade-offs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum, 35, 1117–1123. (1995)CrossRefGoogle Scholar
  7. 7.
    Ozdogan H, Turune M, Deringöl B. et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis; A preliminary open trial. J Rheumatol, 13, 124–125. (1986)PubMedGoogle Scholar
  8. 8.
    Suschke H J, Sulphasalazin bei juveniler chronischer Arthritis. Pädiatr. Prax., 33, 681–684. (1986)Google Scholar
  9. 9.
    Ansell B M, Hall M.A., Loftus J.K. et al. Multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheum, 9, 201–203. (1991)Google Scholar
  10. 10.
    Cassidy J et Petty R. Juvenile rheumatoid arthritis, In: Textbook of pediatric rheumatology, Philadelphia, WB Saunders Co, 133–223. (1995)Google Scholar
  11. 11.
    American College of Rheumatology ad Hoc committee on clinical guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum, 39, 713–722. (1996)CrossRefGoogle Scholar
  12. 12.
    Grönberg A, Almlöf I., Smedegard J. et al. Effects of sulphasalasine on antigen specific and IL2-dependent proliferation of human T cell lines and clones. Arthritis Rheum, 35, suppl (1992)Google Scholar
  13. 13.
    Bradley S M, Neuman V.C., Barr K. et al. Sequential study of bacterial antibody levels and faecal flora in rheumatoid arthritis patients taking sulphasalazine. Brit J Rheum, 32, 683–688. (1993)CrossRefGoogle Scholar
  14. 14.
    Braun J, Sieper J., Doring E. The ethiological role of reactive arthritis-associated bacteria in pauciarticular juvenile chronic arthritis. Arthritis Rheum, 35, 16abstr. (1992)Google Scholar
  15. 15.
    Inman R, The role of infection in chronic arthritis. J Rheumatol, 19, suppl 33, 98–103. (1992)Google Scholar
  16. 16.
    American College of Rheumatology ad Hoc committee on clinical guidelines. Guidelines for monitoring of drug therapy in rheumatoid arthritis. Arthritis Rheum, 39, 723–731. (1996)CrossRefGoogle Scholar
  17. 17.
    Scott D L, Ranay G.S., van Kiel P.L.C.M. et al. Disease activity in rheumatoid arthritis: Preliminary report of the consensus study group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol, 10,521–525.(1992)PubMedGoogle Scholar
  18. 18.
    Scott D L, The variations of clinical measurements. Rheumatology in Europe, 23, 130–135. (1994)Google Scholar
  19. 19.
    Tugwell P and Boers M. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: Introduction. J Rheumatol, 20, 528–529. (1993)PubMedGoogle Scholar
  20. 20.
    Gianini E H, Lovell P.J. Redundancy of the conventional outcome variables used in juvenile rheumatoid arthritis clinical trials. Arthritis Rheum, 37, 9, suppl, 1005 abstr. (1994)Google Scholar
  21. 21.
    Imundo L F, Jacobs J.C. Treatment of juvenile arthritis with sulphasalazine. Arthritis Rheum, 36, 9 suppl 1abstr(1993)Google Scholar
  22. 22.
    Joos R, Veys E.M., Mielants H. et al. Sulphasalazine treatment in juvenile chronic arthritis: An open study. J Rheumatol, 18, 880–884. (1991)PubMedGoogle Scholar
  23. 23.
    Hoza J, Kadlekova T., Nemcova D. et al. Sulphasalazine and Delagil-a comparative study in patients with juvenile chronic arthritis. Acta Universitatis Carolinae-Medica, 37, 80–83. (1991)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Boriana B. Varbanova
    • 1
  • E. D. Dyankov
    • 1
  1. 1.Department of PaediatricsVarna Medical UniversityVarnaBulgaria

Personalised recommendations